See Graham's ranking
4.0
Novartis AG is a Switzerland-based corporation operating in the healthcare sector, with a strategic focus on the pharmaceutical and biotechnology subsectors. The company was formed through the merger of Ciba-Geigy and Sandoz AG, with the objective of consolidating chemical, pharmaceutical, and biotechnological capabilities within an integrated global structure.
The product and service portfolio includes prescription medicines, generics, biosimilars, vaccines, and advanced therapies — including gene and cell therapies — in addition to consumer health products, vision-care solutions, and specialized animal-health segments. Operations encompass advanced research centers, manufacturing facilities, and global logistics networks.
The company serves international markets, maintaining commercial and operational presence across the Americas, Europe, Asia, Africa, and the Middle East. Distribution channels include hospitals, clinics, retail pharmaceutical networks, public healthcare systems, and institutional supply agreements.
Market factors influencing its activity include global health regulation, scientific innovation cycles, competition in the pharmaceutical sector, pricing pressures on generics and biosimilars, research and development costs, patent expirations, public health policies, and rising demand for advanced therapies.
Organizational scale is significant, with approximately 75,000 employees globally. The company’s international footprint reflects substantial production, logistics, and commercial capacity across multiple therapeutic areas.
The operational structure integrates research and development centers, pharmaceutical manufacturing units, biotechnology facilities, distribution hubs, and commercial subsidiaries. The corporate headquarters is located in Basel, Switzerland, with divisions dedicated to innovative medicines, biosimilars, and generics, along with global operations units.
Shares trade under the ticker NVS, representing the company’s primary listing in international markets through ADRs.
History and Foundation
Novartis AG was established in 1996 in Switzerland following the merger of Ciba-Geigy and Sandoz AG, with the aim of integrating industrial and scientific capabilities and forming a global entity focused on pharmaceutical and biotechnological solutions.
In its early years, major challenges included organizational integration, portfolio harmonization, and consolidation of research and production processes. Key achievements involved the initial expansion of the therapeutic portfolio and the standardization of global operations.
Expansion and growth included therapeutic diversification, ongoing investment in scientific innovation, strengthening of biotechnology operations, and the expansion of the generics and biosimilars division through Sandoz. International presence was reinforced with subsidiaries and production centers across multiple regions.
Historical milestones include the 1996 merger, the consolidation of strategic divisions, the launch of innovative therapies across critical medical areas, and the continuous evolution of advanced research and biotechnology units.
Between 2020 and 2024, the company achieved significant progress in specialized therapies, vaccine development, expansion of manufacturing capacity, and strategic adjustments in response to regulatory and market changes. The period also reflected the continuity of robust R&D programs and the preservation of global competitiveness in high-complexity pharmaceutical segments.
Additional Information
The Company Novartis AG (United States), is listed on NYSE with a market value of $ 266.83 Billions, having an equity of $ 44.75 Billions.
With a total of 105.794 employees, the company is listed in the sector of Health and categorized in industry of Main Medications.
In the last 12 months the Company had a revenue of $ 56.37 Billions, which generated a profit in the amount of $ 14.39 Billions.
As for its main indicators, the Company has a P/E ratio of 18.54, a P/BV ratio of 5.96 and in the last 12 months the dividend yield of NVS was at 2.79%.
The Company is traded internationally through the ticker NVS.
